Skip to main content

Glenn Gregory M's Form 4 filing

Novavax Inc (NVAX) · filed Nov 24, 2021

Accession no.
0001209191-21-066826
Filed
Nov 24, 2021
Trade date
Nov 23, 2021
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 9 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.65M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Glenn Gregory MCIK 0001342823Officer (President, R&D)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 23, 2021Common StockMOption exerciseAcquired+8,250$19.08+$157,41012,311Direct
Nov 23, 2021Common StockSSaleDisposed−800$196.43F2−$157,14411,511Direct
Nov 23, 2021Common StockSSaleDisposed−1,400$197.44F3−$276,41610,111Direct
Nov 23, 2021Common StockSSaleDisposed−1,271$198.47F4−$252,255.378,840Direct
Nov 23, 2021Common StockSSaleDisposed−1,387$199.51F5−$276,720.377,453Direct
Nov 23, 2021Common StockSSaleDisposed−1,600$200.55F6−$320,8805,853Direct
Nov 23, 2021Common StockSSaleDisposed−722$201.48F7−$145,468.565,131Direct
Nov 23, 2021Common StockSSaleDisposed−870$202.65F8−$176,305.54,261Direct
Nov 23, 2021Common StockSSaleDisposed−200$203.62F9−$40,7244,061Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 23, 2021Common StockMOption exerciseDisposed−8,250$0.00$099,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $195.90 to $196.89, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F3

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.00 to $197.89, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F4

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.00 to $198.98, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F5

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.01 to $199.99, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F6

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.01 to $200.97, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F7

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.02 to $202.01, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F8

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.04 to $203.00, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F9

The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.30 to $203.93, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)